GV, a corporate venturing subsidiary of internet and technology conglomerate Alphabet, has hired Rosana Kapeller, former chief scientific officer at biotechnology company Nimbus Therapeutics, as its first entrepreneur-in-residence for life sciences.
In her new role, Kapeller will concentrate on technologies that apply machine learning technology to the healthcare and life sciences sectors, with the intention of running a startup developing one of those technologies.
Kapeller spent eight years as the founding chief scientific officer of Nimbus up to March 2018, having previously co-founded peptide drug developer Aileron Therapeutics as vice-president of research, after 10 years at Millennium Pharmaceuticals, which was acquired by Takeda in 2008.
Kapeller has also provided consulting services for venture capital firms Third Rock Ventures and Atlas Venture on their life sciences investments.
Krishna Yeshwant, general partner at GV, told EndPoints News: “We see so many projects either strong on machine learning and weak on development, or vice versa. Rosana has exposure across both cultures.”
GV has also hired David Reshef, a statistician with a PhD from MIT, as a venture partner. He will focus on investments in machine learning technology developers operating in the biotech industry.
Photo of Rosana Kapeller courtesy of GV.